Sample preparation in patients receiving uric acid oxidase (Rasburicase) therapy [2]

Clinical Chemistry

Volumn 49, Issue 8, 2003, Pages 1417-1419

  Lim, EeMun ^a   Bennett, Peter ^a   Beilby, John ^a,b  

^a Western Australian Centre for Pathology and Medical Research   (Australia)

^b PathCentre ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; RASBURICASE; URIC ACID DERIVATIVE;

ADULT; CASE REPORT; CHEMICAL ANALYSIS; COLORIMETRY; DIAGNOSTIC ERROR; FLUID THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERURICEMIA; LETTER; MALE; METABOLIC ACIDOSIS; NONHODGKIN LYMPHOMA; TUMOR LYSIS SYNDROME;

ADULT; BLOOD SPECIMEN COLLECTION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; RECOMBINANT PROTEINS; URATE OXIDASE; URIC ACID;

EID: 0041866755     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.8.1417     Document Type: Letter

References (5)

1. Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 2002;3:433-42.
2. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704.
3. Goldman S, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk of tumor lysis. Blood 2001;97:2998-3003.
4. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001;15:1505-9.
5. Easton J, Noble S, Jarvis B. Rasburicase. Paediatr Drugs 2001;3:433-7.